Literature DB >> 7979946

Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established.

P C Ridings1, A C Windsor, H J Sugerman, E Kennedy, M M Sholley, C R Blocher, B J Fisher, A A Fowler.   

Abstract

OBJECTIVE: To determine the effects of pretreatment and posttreatment with pentoxifylline in a porcine model of gram-negative sepsis.
DESIGN: Nonrandomized controlled trial. STUDY
SUBJECTS: Young Yorkshire swine.
INTERVENTIONS: Six groups of ventilated swine were studied for 5 hours. Group 1 swine (control, n = 8) received saline solution only. Group 2 swine (sepsis, n = 8) received a 1-hour infusion of Pseudomonas aeruginosa. Groups 3, 4, and 5 swine received the P aeruginosa infusion and a 20 mg/kg bolus followed by a 6 mg/kg per hour infusion of pentoxifylline. Group 3 swine (n = 6) received pentoxifylline prior to the onset of sepsis; group 4 swine (n = 6) received pentoxifylline at 1 hour and group 5 swine (n = 4) at 2 hours after the onset of the P aeruginosa infusion. Group 6 swine (control pentoxifylline, n = 3) received pentoxifylline only. OUTCOME MEASURES: Hemodynamic variables, neutrophil counts and CD18 expression, tumor necrosis factor activity, and arterial blood gases were measured hourly. Bronchoalveolar lavage was performed at 0 and 5 hours to measure neutrophil and protein content.
RESULTS: All variables remained unchanged in the control and control pentoxifylline groups. Both pretreatment and posttreatment with pentoxifylline significantly attenuated lung injury and improved arterial PaO2. The cardiac index was significantly improved by administration of pentoxifylline in groups 3 and 4. Administration of pentoxifylline to group 5 animals in established septic shock caused uncontrolled, fatal systemic hypotension in two of the four animals. Plasma tumor necrosis factor activity, blood polymorphonuclear leukocyte counts, and CD18 expression were unaffected by the administration of pentoxifylline.
CONCLUSIONS: Pentoxifylline protects against pulmonary and systemic hemodynamic derangements in fulminant sepsis and protects against pulmonary dysfunction. Pentoxifylline has a "therapeutic window" when given in established sepsis; if administration is delayed until overt septic shock occurs, it may then have deleterious effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979946     DOI: 10.1001/archsurg.1994.01420350042004

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Studies of skin-window exudate human neutrophils: increased resistance to pentoxifylline of the respiratory burst in primed cells.

Authors:  A Carletto; D Biasi; L M Bambara; P Caramaschi; M L Bonazzi; S Lussignoli; G Andrioli; P Bellavite
Journal:  Inflammation       Date:  1997-04       Impact factor: 4.092

Review 2.  Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research.

Authors:  Swantje Voller; H Rob Taal; Serife Kurul; Kinga Fiebig; Robert B Flint; Irwin K M Reiss; Helmut Küster; Sinno H P Simons
Journal:  Pediatr Res       Date:  2021-09-08       Impact factor: 3.756

3.  A rabbit model of non-typhoidal Salmonella bacteremia.

Authors:  Aruna Panda; Ivan Tatarov; Billie Jo Masek; Justin Hardick; Annabelle Crusan; Teresa Wakefield; Karen Carroll; Samuel Yang; Yu-Hsiang Hsieh; Michael M Lipsky; Charles G McLeod; Myron M Levine; Richard E Rothman; Charlotte A Gaydos; Louis J DeTolla
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2014-07-03       Impact factor: 2.268

4.  Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial).

Authors:  Serife Kurul; H Rob Taal; Robert B Flint; Jan Mazela; Irwin K M Reiss; Karel Allegaert; Sinno H P Simons
Journal:  BMC Pediatr       Date:  2021-11-18       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.